1%

Question 1 of 60

The following are licensed in the UK for the management of obesity:

Rationale:
Orlistat is licensed in the UK for the management of obesity. This medication works by inhibiting the absorption of dietary fats, thereby promoting weight loss effectively when combined with a reduced-calorie diet and exercise. B: Sibutramine This appetite suppressant was withdrawn from the market due to safety concerns, specifically cardiovascular risks, making it unsuitable for obesity management in the UK. C: Thiazide diuretics Primarily used to treat hypertension, thiazide diuretics do not address obesity directly and can lead to weight gain due to fluid retention, which detracts from weight loss efforts. D: Pizotifen Though indicated for migraine prevention, pizotifen is not approved for obesity management and may actually contribute to weight gain, making it inappropriate for this purpose.